Geniposide improves hepatic inflammation in diabetic db/db mice

Area of Science:

• Biochemistry
• Pharmacology
• Hepatology

Background:

• Diabetic liver injury is a growing concern with complex pathological mechanisms.
• Inflammation and metabolic dysregulation are key contributors to liver damage in diabetes.

Purpose of the Study:

• To investigate the protective effects of geniposide (GE) on liver injury in diabetic mice.
• To elucidate the underlying molecular mechanisms of GE's hepatoprotective action.

Main Methods:

• Oral glucose tolerance tests were conducted.
• Biochemical assays measured insulin, ALT, AST, TC, and TG levels.
• Western blotting analyzed the expression of Rho/ROCK and NF-κB signaling pathway proteins.

Main Results:

• Geniposide (GE) treatment significantly reduced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in diabetic mice.
• GE reversed the expression of Rho, ROCK1, ROCK2, p-NF-κBp65, and p-IκBα.
• Metabolic parameters and liver enzymes showed improvement with GE treatment.

Conclusions:

• Geniposide (GE) demonstrates significant hepatoprotective effects against inflammation in diabetic liver injury.
• GE likely exerts its protective effects by modulating the Rho/ROCK and NF-κB signaling pathways.
• GE represents a potential therapeutic agent for managing diabetic hepatic complications.